参考文献/References:
［1］Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］.CA-A Cancer Journal for Clinicians, 2018,68(6):394-424.
［2］Torre L A, Islami F, Siegel R L, et al.Global cancer in women: burden and trends ［J］.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2017, 26(4): 444-457.
［3］Fitzmaurice C, Collaboration G B, Allen C, et al.Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted life-years for 32 cancer groups, 1990 to 2015 a systematic analysis for the global burden of disease study ［J］.JAMA ONCOLOGY, 2017, 3(4): 524-548.
［4］Krepler C, Sproesser K, Brafford P, et al.A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma ［J］.Cell Reports, 2017, 21(7): 1953-1967.
［5］Clohessy J G， Pandolfi P P.Mouse hospital and co-clinical trial project–from bench to bedside ［J］.Nat Rev Clin Oncol， 2015, 12(8):491–498.
［6］Gao H, Korn J M, Ferretti S, et al.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response ［Z］, 2015: 1318.
［7］Jung J, Jang K, Ju J M, et al.Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model ［J］.Cancer Letters, 2018, 428（1）：127-138.
［8］Knudsen E S, Balaji U, Mannakee B, et al.Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility ［J］.Gut, 2018, 67(3): 508-520.
［9］Zou Jianling, Liu Ying, Wang Jingyuan, et al.Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization ［J］.Journal of Translational Medicine, 2018, 16(1): 15.
［10］ Kasai N, Sasakawa Aya, Hosomi K, et al.Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer ［J］.American Journal of Translational Research, 2017, 9 (7): 3399-3410.
［11］Burgenske D M, Monsma D J, Mackeigan J P.Patient-derived xenograft models of colorectal cancer: procedures for engraftment and propagation ［J］.Methods in Molecular Biology (Clifton, N.J.), 2018, 1765: 307-314.
［12］Lee S H, Hu Wen-huo, Matulay J T, et al.Tumor evolution and drug response in patient-derived organoid models of bladder cancer ［J］.Cell, 2018, 173(2): 515.
［13］Xu Linfeng, Meng Xiaoxiao, Xu Naihan, et al.Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth ［J］.Cell Death & Disease, 2018, 9(3): 262.
［14］Wu Licun, Allo G, John T, et al.Patient-Derived xenograft establishment from human malignant pleural mesothelioma ［J］.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017, 23(4): 1060-1067.
［15］Swick A D, Stein A P, Mcculloch T M, et al.Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts ［J］.Oral Oncology, 2017, 64: 65-72.
［16］Patrizii M, Bartucci M, Pine S R, et al.Utility of glioblastoma patient-derived orthotopic xenografts in drug discovery and personalized therapy ［Z］, 2018: 00023.
［17］Ito M ,Hiramatsu H， Kobayashi K， et al.NOD/SCID/yc cnull mouse: An excellent recipient mouse model for engraftment of human cells ［J］.Blood, 2002, 100(9):3175-3182.
［18］Seiji Okada, Hideki Harada, Takaaki Ito, et al.Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3nullmice intrahepatic engrafted with cord blood-derived CD34+cells ［J］.International Journal of Hematology,2008,88(5):476-482.
［19］师长宏.肿瘤患者来源的异种移植（PDX）模型 ［J］.实验动物与比较医学,2018,38(3):165-168.
［20］Ibarrola-villava M, Cervantes A, Bardelli A.Preclinical models for precision oncology ［J］.Biochimica et Biophysica Acta-Reviews on Cancer, 2018, 1870(2): 239-246.
［21］Jun E, Jung J, Jeong S, et al.Surgical and oncological factors affecting the successful engraftment of patient-derived xenografts in pancreatic ductal adenocarcinoma［J］.Anticancer Research, 2016, 36(2): 517-521.
［22］郭艳敏，周梅香．p16、Ki-67在宫颈上皮内病变中的表达及意义 ［J］．诊断病理学杂志，2017，24（2）：105-107．
［23］Wang Zhi-lian, Wang Jin-tao, Fan Jin-rong, et al.Risk factors for cervical intraepithelial neoplasia and cervical cancer in Chinese women: large study in Jiexiu, Shanxi Province, China ［J］.Journal of Cancer, 2017, 8(6): 924-932.
相似文献/References:
[1]冯学宇,乔银川,王好宁,等.823例宫颈癌机会性筛查结果分析[J].中国计划生育和妇产科,2010,(01):0.
FENG Xue-yu,QIAO Yin-chuan,WANG Hao-ning ..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(3):0.
[2]刘佳汭.保留盆腔自主神经的宫颈癌根治性手术[J].中国计划生育和妇产科,2010,(02):0.
[3]甘玉杰,熊小英,蔡春芳,等.血清SCCA、CA125、CA19-9与高危型人乳头状瘤病毒在宫颈癌及癌前病变中的表达及意义[J].中国计划生育和妇产科,2010,(04):0.
GAN Yu-jie,XIONG Xiao-ying,CAI Chun-fang,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(3):0.
[4]肖春燕,陈桂珍,铁木帅龙,等.325例宫颈病变阴道镜检查结果分析[J].中国计划生育和妇产科,2010,(05):0.
XIAO Chun-yan,CHEN Gui-zhen,TIEMU-Shuailong.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(3):0.
[5]胡玲,胡健蓉,徐凤仪,等.血管内皮生长因子在子宫内膜癌中的表达及其意义[J].中国计划生育和妇产科,2011,(01):0.
HU Ling,HU Jian-rong,XU Feng-yi,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(3):0.
[6]孙红敏,苑中甫.胰岛素样生长因子受体-1在子宫内膜癌组织中的表达及意义[J].中国计划生育和妇产科,2011,(02):0.
SUN Hong-min,WAN Zhong-fu ..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(3):0.
[7]田兆华,王建六.应客观评价腹膜后淋巴结切除在子宫内膜癌的治疗价值[J].中国计划生育和妇产科,2011,(03):0.
[8]陈晓丽.CD44v6、MMP-2在子宫内膜癌的表达及临床意义[J].中国计划生育和妇产科,2011,(03):0.
CHEN Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(3):0.
[9]梅彤,舒宽勇.CD133在子宫内膜癌中的研究进展[J].中国计划生育和妇产科,2012,(04):0.
MEI Tong,SHU Kuan-yong* .Medical.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(3):0.
[10]钟茜,赵霞.宫颈癌诊治中的过度治疗与治疗不足[J].中国计划生育和妇产科,2013,(02):0.
ZHONG Xi,ZHAO Xia,[J].Chinese Journal of Family Planning & Gynecotokology,2013,(3):0.